Market Research Finds 99% Of US Clinical Cardiologists Surveyed Report a High Unmet Need for New Innovative Drug Treatments for Early Cardiogenic Shock Patients (ECS) as Windtree Therapeutics Prepares for Clinical Results from its Istaroxime ECS Study
Cardiogenic Shock Worldwide Total Market Value Is Estimated To Be $1.25 BillionWARRINGTON, Pa., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Windtree...